Navitoclax - Wikipedia
Navitoclax (previously ABT-263) is an experimental orally active anti-cancer drug, which is a Bcl-2 inhibitor similar in action to obatoclax. [1] [2]
Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic …
Navitoclax is a very potent BH3 mimetic drug that could inhibit BCL-X L in myofibroblasts and eventually lead to the apoptosis of myofibroblasts (Lagares et al., 2017). Navitoclax acts on …
Navitoclax: Uses, Interactions, Mechanism of Action - DrugBank …
Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks …
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for …
Feb 18, 2022 · Navitoclax (ABT-263) is an orally bioavailable, small-molecule BCL-2 homology 3 mimetic that binds with high affinity (K i ≤ 1 nmol/L) to prosurvival BCL-2 family proteins (BCL …
Safety, Pharmacokinetics, Pharmacodynamics, and Activity of Navitoclax ...
Navitoclax (ABT-263) is a targeted high-affinity small molecule that occupies the BH3 binding groove of BCL-2 and BCL-X L and inhibits their anti-apoptotic activity. Experimentally, …
New era for myelofibrosis treatment with novel agents beyond …
Aug 16, 2023 · This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-X L) in disease pathogenesis and the potential role that navitoclax, a BCL-extra …
Navitoclax | C47H55ClF3N5O6S3 | CID 24978538 - PubChem
Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks …
Navitoclax - an overview | ScienceDirect Topics
Navitoclax (ABT-263) is the first-generation, oral, BH3 mimetic that inhibits Bcl-2, Bcl-XL, and Bcl-w, but not Mcl-1. In a phase I study of 55 patients with relapsed lymphoid malignancies, …
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid ...
Navitoclax is a targeted high-affinity small molecule that inhibits the anti-apoptotic activity of BCL-2 and BCL-XL. We aimed to assess the safety and antitumour activity of navitoclax in patients …
Navitoclax and Ruxolitinib Show Potential in Treating R/R …
Nov 29, 2024 · Navitoclax and ruxolitinib combination therapy showed durable responses and potential disease modification in relapsed/refractory myelofibrosis. The combination therapy …